Expertise in
4
conditions

Alvaro Taus

Barcelona, CT, ES 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
4
conditions
Barcelona, CT, ES 

Overview

Alvaro Taus practices practicing medicine in Barcelona, Spain.

Mr. Taus is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Lung Adenocarcinoma, Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), and Tissue Biopsy.

He is actively involved in clinical research, co-authoring 50 peer reviewed articles and participating in 4 clinical trials.

Gender

Male

Locations

Barcelona, CT, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: June 27, 2025
Intervention Type: Drug
Study Drug: APL-101
Study Phase: Phase 2
Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Enrollment Status: Active_not_recruiting
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drugs: X-396 (Ensartinib), Crizotinib
Study Phase: Phase 3
Retrospective, Observational Study On The Efficacy And Safety Of Lorlatinib In ALK or ROS1 Metastatic Non-Small Cell Lung Cancer Patients Treated Within The Compassionate Use Program In Spain
Retrospective, Observational Study On The Efficacy And Safety Of Lorlatinib In ALK or ROS1 Metastatic Non-Small Cell Lung Cancer Patients Treated Within The Compassionate Use Program In Spain
Enrollment Status: Completed
Publish Date: March 30, 2023
Intervention Type: Drug
Spanish Real World Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy.
Spanish Real World Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy.
Enrollment Status: Completed
Publish Date: June 07, 2022
Intervention Type: Drug
View 3 Less Clinical Trials

50 Total Publications

Brief report: Artificial intelligence meets small cell lung cancer-integrating clinicopathological and wholeslide image data for prognostic prediction in SCLC.
Brief report: Artificial intelligence meets small cell lung cancer-integrating clinicopathological and wholeslide image data for prognostic prediction in SCLC.
Journal: Frontiers in artificial intelligence
Published: December 12, 2025

Frequently Asked Questions about Alvaro Taus

Is Alvaro Taus a top-rated expert for Lung Adenocarcinoma?

MediFind is an objective health platform that identifies experts based on real-world data. Alvaro Taus is classified as an Distinguished expert for Lung Adenocarcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Alvaro Taus participate in research or clinical trials?

Yes. Alvaro Taus has published 50 articles and abstracts on conditions like Lung Adenocarcinoma. You can view a list of Alvaro Taus's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Taus's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile